Answers are grounded in this paper and cite their sources.
Sialic acids trace the evolutionary arc of contemporary glycoscience and continue to provide inspiration for drug discovery. However, harnessing the potential of sialic acids in a therapeutic context is contingent on unlocking chemical space and devising strategies that allow the venerable C9 framework to be selectively modified in an operationally simple manner. Enabled by judicious C(sp3)-F installation at C3, the configuration of this center can serve as a lever to facilitate a series of structural editing events in a programmable fashion. This is exemplified by the regiodiversity of amide cyclization: (R)-configuration → 5-membered ring formation; (S)configuration → 7-membered ring formation with concomitant acetyl migration, to access bridged-bicyclic scaffolds that are reminiscent of naturally occurring sialic acids. Importantly, this [CH2 → CHF] isosteric replacement enables selective modification at C2 (glycosylation), C4 (epimerization) and C5 (N-deacetylation). Given the ubiquity of C3 fluorinated sialic acids in chemical biology and biomedicine, it is envisaged that this conceptual framework will expedite chemical space exploration.
No takes yet. Share an insight, caveat, or question.
Chikunova et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: